XOMA Royalty Corp.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- XOMA Royalty Corp. (NASDAQ: XOMA) operates as a biotechnology royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology partners; provides non-dilutive, non-recourse funding to sellers to advance drug programs or for corporate purposes; and maintains a diversified portfolio exceeding 120 assets across early- to late-stage development, including commercial products such as VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate vaginal gel 2%), IXINITY (coagulation factor IX recombinant), and DSUVIA (sufentanil sublingual tablet), as well as Phase 3 and earlier assets like mezagitamab (Takeda), ersodetug (Rezolute), seralutinib (Gossamer Bio), and others in oncology, rare diseases, and metabolic disorders. The company, founded in 1981 and headquartered at 2200 Powell Street, Suite 310, Emeryville, California, transformed its business model in 2017 from a traditional biotech developer to a royalty-focused aggregator and changed its name from XOMA Corp. to XOMA Royalty Corp. in July 2024. XOMA Royalty targets biotech firms globally, with operations centered in the United States and Asia Pacific, employing a capital-efficient structure where partners bear all R&D costs. Recent developments include the May 2025 acquisition of mezagitamab royalty and milestone rights from BioInvent International for $20 million upfront plus a potential $10 million regulatory milestone, entitling XOMA Royalty to up to $16.25 million in milestones from Takeda and mid-single-digit royalties on sales for chronic immune thrombocytopenia; pending acquisitions of Turnstone Biologics (closed August 2025 for $0.34 per share plus CVR), HilleVax (expected September 2025 for $1.95 per share plus CVR), and LAVA Therapeutics (expected Q4 2025 for $1.16-$1.24 per share plus CVR), securing interests in partnered assets like Pfizer's PF-08046052 and Johnson & Johnson's JNJ-89853413; structuring financing for XenoTherapeutics' acquisition of ESSA Pharma; and sale of remaining Kinnate pipeline assets for up to $270 million in payments plus royalties. Pipeline milestones encompass Rezolute's completion of Phase 3 sunRIZE enrollment for ersodetug in congenital hyperinsulinism (topline data expected December 2025, yielding a $5 million payment), EMA acceptance of Day One/Ipsen's tovorafenib MAA ($4 million milestone), Zevra's arimoclomol MAA submission, and Takeda dosing the first patient in mezagitamab's Phase 3 ITP trial ($3 million net milestone). In the first half of 2025, XOMA Royalty received $29.6 million in cash from royalties and milestones, repurchased over 107,500 common shares, and held $78.5 million in cash equivalents as of June 30, 2025.
Saying Goodbye To The XOMA Royalty PFDs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders
XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
XOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
2 Royalty Income Streams You Don't Have To Work For
XOMA Royalty (NASDAQ:XOMA) Stock Passes Above 200 Day Moving Average – Here’s Why
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update